Annual report for Zydus Wellness Ltd. for FY-2021
10-05-2021
Zydus wrapping up Phase-III trials of three-dose vaccine'
Says non-needle antidote will provide wider and longer antibody response07-05-2021
Zydus Wellness Ltd - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Post Results Investor Meet /Call.05-05-2021
Zydus Wellness Ltd - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Notice for loss of share certificate.05-05-2021
Zydus may seek jab nod this month
The Ahmedabad-based drugmaker had started the 28,000-participant phase 3 trial of its DNA plasmid vaccine in February05-05-2021
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Board Meeting of the Company in Financial Express.04-05-2021
Zydus Wellness Ltd - 531335 - Board Meeting Intimation for Board Meeting Intimation For Considering Audited Results And Dividend, If Any.
ZYDUS WELLNESS LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2021 ,inter alia, to consider and approve Board Meeting Intimation for Considering Audited Results and Dividend, if any.03-05-2021
Zydus gets EUA for single-dose 'Virafin' to treat moderate Covid infection
The company says a single dose of the antiviral Virafin administered subcutaneously early on shows significant clinical and virological improvement in moderate Covid-19 adult patient23-04-2021
Zydus Wellness Ltd - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of notice to Shareholder to claim dividend.14-04-2021
ZYDUS WELLNESS LTD.-$ - 531335 - Compliance Certificate From PCS Under Reg. 40(10)
Compliance Certificate from PCS under Reg. 40(10)09-04-2021